

TOLWIŃSKI, Ignacy, DADAS, Klaudia, ŚWIERCZ, Aleksandra, ŻUREK, Urszula, KĘDZIERSKA, Zofia, MAŁACHOWSKA, Dominika, CIECIERSKI-KOŹLAREK, Hubert, ANTKOWIAK, Klaudia, POPCZYŃSKA, Justyna, WOŹNIAK, Kinga, HEDESZ, Patryk, TARAS, Andrzej and SHVED, Kateryna. Depression development in patients with OA, and its impact on treatment outcome - a literature review. *Journal of Education, Health and Sport*. 2023;26(1):111-128. eISSN 2391-8306. DOI <http://dx.doi.org/10.12775/JEHS.2023.26.01.011> <https://apcz.umk.pl/JEHS/article/view/44814> <https://zenodo.org/record/8173771>

The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 17.07.2023 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences). Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 17.07.2023 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przynależność dyscypliny naukowej: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).

© The Authors 2023;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (<http://creativecommons.org/licenses/by-nc-sa/4.0/>) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 28.06.2023. Revised: 20.07.2023. Accepted: 20.07.2023. Published: 25.07.2023.

Depression development in patients with OA, and its impact on treatment outcome- a literature review

1. Ignacy Tolwiński* (1) 0000-0003-1362-6734 ignacyt233@gmail.com
2. Klaudia Dadas (1) 0009-0007-3352-9807 klaudia.w.2703@gmail.com
3. Aleksandra Świercz (1) 0009-0007-1535-1590 aleksandra.swiercz1996@gmail.com
4. Urszula Żurek (1) 0009-0008-3482-5381 ula.zurek@gmail.com
5. Zofia Kędziarska (1) 0000-0002-4181-4719 zo.kedziarska@gmail.com
6. Dominika Małachowska (1) 0009-0008-6305-7959
dominika1.malachowska@gmail.com
7. Hubert Ciecierski-Koźlarek (2) 0009-0009-4062-6888 hubertciecierski@icloud.com
8. Klaudia Antkowiak (3) 0009-0008-3421-2200 klaudia.antkowiak@gmail.com
9. Justyna Popczyńska (4) 0009-0008-7654-923X jpopczynska@gmail.com
10. Kinga Woźniak (5) 0009-0007-9802-5888 kingawozniak96@gmail.com
11. Patryk Hedesz (6) 0009-0006-1886-0916 p.hedesz@gmail.com
12. Andrzej Taras (7) 0009-0001-4868-7281 andrzejtaras1993@gmail.com
13. Kateryna Shved (8) 0009-0002-3773-7025 katey.shved@gmail.com

1. Warszawski Szpital Południowy, ul. rtm. Witolda Pileckiego 99, 02-781 Warszawa
2. Wojewódzki Szpital Specjalistyczny w Olsztynie, ul. Żołnierska 18, 10-561 Olsztyn
3. Szpital Średzki Serca Jezusowego, ul. Żwirki i Wigury 10, 63-000 Środa Wielkopolska
4. Warszawski Uniwersytet Medyczny, ul. Żwirki i Wigury 61, 02-091 Warszawa

5. SPZZOZ Szpital Powiatowy im. Marii Skłodowskiej-Curie w Ostrowi Mazowieckiej, ul. Stanisława Dubois 68, 07-300 Ostrów Mazowiecka

6. Zespół Opieki Zdrowotnej „Szpitala Powiatowego” w Sochaczewie, ul. Batalionów Chłopskich 3/7, 96-500 Sochaczew

7. Mazowiecki Szpital Wojewódzki w Siedlcach Sp. z o.o. Siedlecki Szpital Specjalistyczny, ul. Poniatowskiego 26, 08-110 Siedlce

8. Wielospecjalistyczny Szpital Miejski im. Józefa Strusia, ul. Szwajcarska 3, 61-285 Poznań, Poland

*Correspondence: ignacyt233@gmail.com

Abstract

Introduction and aim of the study:

Osteoarthritis (OA) and depression are leading causes of disease burden worldwide and important public health problems. A number of recent studies reported depression as a comorbidity of OA and its impact on reduced quality of life and worse treatment outcome of OA patients. The clinical management strategies of those patients still haven't been developed, which is a challenge of future research on this topic. The aim of this review is to shed a light on important aspects of depression relationship with OA including its prevalence among OA patients and its influence on course and treatment of OA with a purpose of increasing awareness of this problem among physicians which may subsequently lead to a better overall medical care of patients with OA and depression.

Methods and materials:

This literature review is based on articles published in the PubMed database, GoogleScholar, ScienceDirect, and available medical textbooks.

Conclusions:

Recent literature reports a higher prevalence of depression among OA patients when compared to general population and its impact on osteoarthritis course, both on psychological and biomolecular level. Future research may lead to a better understanding of molecular background of depression and OA interrelation and to more complex and individualized

management strategies which may result in a better outcome of treatment and improved life quality of osteoarthritis patients. Therefore, in order to optimize management of OA patients, physicians should pay more attention to depression and use multidisciplinary approach including assessment of mental health status to develop a more effective strategies of medical care in osteoarthritis.

Key words: osteoarthritis, depression, impact, epidemiology, management

1. Introduction

Osteoarthritis (OA) is a multifactorial joint disease that affects quality of life of millions of people around the world, with a higher prevalence among older individuals, women, some racial and ethnic groups, and individuals with lower socioeconomic status[1]. It is estimated that there are 240 million individuals with OA, including 10% and 18% of men and women among age 60 respectively, making it the most common musculoskeletal disease [2]. Furthermore, OA is placed among top 10 disabilities worldwide. It is predicted that its prevalence will increase due to rising problem of OA risk factors such as aging of population and emerging problem of obesity[3]. Literature characterized OA as structural changes at the level of a joints which result in broad spectrum of symptoms including joint pain, stiffness, swelling, reduced joint range of motion, that subsequently lead to many functional limitations that impair ability to participate in physical activities and finally make walking impossible[4]. Not only does it increase risk of progression of OA and cardiometabolic diseases but also influences quality of life on many other levels[4]. OA is associated with serious physical limitations[5] and also with many psychological problems including poor quality of sleep, fatigue[6, 7], anxiety and depression[8].

Similarly to osteoarthritis, depression is a major global issue and its prevalence is growing rapidly[9]. More and more studies are focusing on depression association with OA[10, 11], its influence on course of this disorder[12], and impact on symptoms such as pain, stiffness and limitation of activities[13, 14]. As recent systematic review reports 19.9% (95% CI: 15.9–24.5%) of people with OA had depressive symptoms, with a higher relative risk of depression occurrence in those with OA compared to those without[8]. Literature has already shown that OA is not the only musculoskeletal disease with depression possible contribution to its course as rheumatoid arthritis (RA) and established comorbid depression were associated with poorer outcome of RA management[15]. Even though depression association with OA has been

reported by many studies, according to Gleicher et al only half of OA patients with probable depression received mental health support[12]. It is not satisfactory number as recent studies show possible role of cognitive behavioral therapy, exercise and integrated depression management in improving outcome of patients with comorbid depression in OA[16].

The aim of this study is to review articles on depression prevalence among patients with OA and address the issue of its impact on OA symptoms severity, its course and treatment options.

2. OA and depression: Epidemiology

Osteoarthritis is a highly prevalent disease, and it is the most common form of arthritis. It is estimated that nearly 240 million people around the world are diagnosed with OA. In addition, literature proved relationship between age, low socioeconomic status, sex and higher possibility of OA onset[17-19]. Furthermore, OA is placed as one of the world's leading causes of disability, it accounts for 2,4% of all years lived with disability (YLD)[20, 21]. It is also third most rapidly rising condition associated with disability after diabetes and dementia with 75% increase of OA, related in years 1990-2013[20]. Comparably to OA, depression is one of a leading public health problems and it is one of the main causes of disease burden in recent years[22, 23]. It's prevalence is rising as depressive symptoms among adolescents increased from 24% (95% CI: 0.19-0.28) between 2001 and 2010 to 37% (95% CI: 0.32-0.42) between 2011 and 2020[24]. Depression association with OA is getting more and more highlighted. In recent systematic review by Stubbs et al authors estimated that prevalence of depression in patients with OA is 19,9% (95% CI: 15.9–24.5%)[8]. Mixed lower limb osteoarthritis was more associated with depression when compared to isolated knee osteoarthritis, where pooled prevalence of depressive symptoms was 23% (95% CI: 16.4% to 30.2%; I²:95.8%) and 18.5% (95% CI: 13.8% to 23.7%; I²:85.4%) respectively[8]. In cross-sectional survey of 1,021 patients with OA Roseman et al reported that prevalence of depression among OA patients was 19.76% of male and 19.16% of female participants, those patients reported a PHQ-9 score of ≥ 15 [25]. Similar results were presented by Sale et al in cross-sectional study as among 1227 individuals with OA 21,3% scored ≥ 16 in CES-D scale, which supports depressed mood[14]. Total joint replacement (TJR) is a treatment for end-stage OA. In study by Gad B.V. et al 21% of patients awaiting TJR had concomitant physician-reported depression[26]. Kirkness et al confirmed those results as among patients scheduled for total knee arthroplasty comorbid depression was highly prevalent[27]. Scott et al in their meta-analysis reported that 23% of TJR patients had diagnosed depression before

surgery and one year later depression prevalence among those patients decreased to 13%[28]. In recent years number of studies have touched on topic of depression development and prevalence in patients with OA. Zheng S et al in his study estimated that in patients with knee OA the presence and incidence of depression was 25.4 and 11.2%, respectively[11]. As literature reports the disease burden of OA is similar when compared to rheumatoid arthritis (RA)[29, 30]. In addition, review by Matcham et al showed that depression is highly prevalent among RA patients and it is associated with poorer outcomes of this disease treatment[15].

3. Comorbid depression in osteoarthritis: Risk factors

Numerous studies have explored factors that may affect depression prevalence among OA patients. Lower education level, obesity, female sex and age were proven to be risk factors for both OA and depression[31]. One of the most researched factors contributing to development of OA and depression is having higher BMI[32, 33]. Literature explains this phenomenon as OA, depression and obesity might share common pathophysiology which involve increase in several proinflammatory cytokines that subsequently lead to various complications including inflammation-induced cartilage catabolism in the knee[34-39]. Moreover, Jacobs et al used novel approach to identify structural changes in knee osteoarthritis (KOA) as they compared non-obese patients, obese patients without depression and obese patients with depressed mood, in two years follow up. Results showed that among those 3 groups obese patients with depression had significantly worse symptoms. Authors explained their results using inflammatory theory to combine those three disorders. Increased excretion of collagen terminal peptide markers was observed in the urine of obese patients with depression, which suggests more severe progression of cartilage damage. These results show that depression might increase inflammatory burden in patients with OA and obesity and lead to increased possibility of more severe cartilage degeneration[40].

Second risk factor of depression in OA patients that literature reports is female sex. Recent longitudinal study by Li M et al among others highlighted female sex as a potential risk factor of depression in OA[41]. Furthermore, Sale et al reported that higher probability of concomitant depression in OA was independently and significantly associated with the female sex[14]. In addition, Zheng et al in his recent study confirmed those results as being a woman was associated with higher incidence of depression among patients with knee OA[11]. However, results are inconsistent as Parmelle et al reported that women experienced greater

pain and marginally greater disability than men, but there was lack of proven relationship between sex and higher prevalence of depression in studied group[42]. One theory that might explain differences of depression prevalence between men and women with OA is associated with estrogen and its receptors. Recent scientific evidence indicate estrogen involvement in depression pathophysiology[43]. First of all, estrogen might influence serotonin receptors number and function[44] and fluctuating concentration of estrogen was associated with depressed mood[45]. What's more estrogen receptor α (ESR1) has been reported to have a relationship with major depressive disorder(MDD)[46]. Estrogen and its receptors not only play a role in sexual and reproductive functions but also in other tissues such as bones. ESR1 is expressed in chondrocytes, stromal cells, and osteoblasts[47] and its genetic variants have been reported to impact OA[48, 49].

When it comes to aging, it is proven risk factor of OA. On the other hand, in depression, overall prevalence is lower in elderly than younger people[50]. Nevertheless, coexisting comorbidities among elderly people elevate risk of depression[51]. Rosemann T et al in their study reported that increasing age in OA was a lower predictor of PHQ-9 scores[25]. To conclude, it is important to remember about higher prevalence of depression among younger patients with OA.

Pain and correlating physical limitation are also proven risk factors of depression prevalence among patients with OA. Hawker et al reported that pain in OA induced future fatigue, disability, and depressed mood[13]. Pain itself was reported by literature to have a relationship with depression[52, 53]. Fonseca-Rodrigues D et al in their systematic review demonstrated a significant correlation between pain and depression/anxiety severity in OA patients[54]. Many more studies touched on pain, depression and OA interrelations[11, 25, 55]. Walking difficulty occur as result of a severe pain in OA patients [56], and it itself may contribute to worsening of depressive symptoms among them[57]. Mobility impairment is a proven risk factor for physical limitation[58]. Physical activity, on the other hand, is a proven factor which influences depression course[59]. Above-mentioned studies show that management of pain and joint dysfunctions might contribute to improvement of depressive symptoms[60].

4. Mechanisms of depression development in patients with OA

Development of depression symptoms in patients with OA might be mediated by various multifactorial mechanisms which are not yet fully understood. As there are many reasons why OA patients could develop depression, it is believed that comorbidity of OA and depression may be mediated by biological, sociological, psychological and behavioral mechanisms which lead to various etiologies and risk factors[22, 61]. Negative impact on depression course, prevalence and treatment outcome of chronic diseases has been reported by studies in the past[52, 62].

There are several theories on biological link between those two disorders. First, the involvement of inflammatory mediators and inflammatory theory as potential compound in pathophysiology of OA have been reported by literature in the past[63, 64]. Recent research by Chow Y.Y. and Chin K.Y. identified inflammatory mediators found in OA patients which include tumor necrosis factor- α , interleukin-6, and interleukin-1 β [65]. Furthermore, Shimura et al reported that patients with knee osteoarthritis with comorbid depression, had a higher serum interleukin-6 levels than patients with OA alone. Lastly, D'Mello and Swain et al proposed mechanism in which inflammation contributes to development of depression[66]. That may explain inflammatory response as a possible cause of correlation between OA and depression. Another proposed mechanism of comorbidity of OA and depression relates to elevated serum concentration of cortisol. Villafañe JH et al in their review explored cortisol contribution to pathophysiology of osteoarthritis. Even though, there wasn't enough evidence to support relationship between cortisol and OA, they reported significantly increased cortisol level in patients with pain, which is one of the main OA symptoms. Furthermore, there are some studies that prove elevated cortisol serum levels in patients with depression[67, 68]. Therefore, variations in serum cortisol contraction might contribute to concomitant depression in OA patients. Gerrits MM et al suggested that not chronic disorder itself but pain as a result of chronic disease contributes to depressive symptoms development[52]. There is multifactorial explanation on why pain could impact depression prevalence among OA patients. Biological point of view suggests that pain may cause changes such as dysregulation of the HPA axis (by increasing cortisol) and dysregulation of the HPA axis is one of the proposed mechanisms of depression development[69]. To back this up K. Wingenfeld et al in their research showed a relationship between self-reported depression and reactivity of the HPA axis in patients with chronic pelvic pain[70]. Furthermore, studies have shown that pain has impact on neuronal pathways and brain function in areas of cognition and emotion.

Neuroimaging studies have shown significant change in prefrontal cortex and hippocampus as a result of experienced pain[71, 72]. In MRI scan study, hippocampal volume decreased faster in patients with OA when compared to patients without OA and with normal cognition[73]. As above-mentioned studies show there are brain structure and function changes in patients with OA and co-existing pain which might contribute to comorbidity of OA and depression. Hawker A. et al in their original article assessed relationship between pain, fatigue and depression on large sample size of community based older adults with OA, using wide range of scales (WOMAC, MFSI-SF and CES-D). They reported a direct link between pain and subsequent depressed mood through pain-fatigue-disability-depression cycle and emphasized need for a multidimensional approach to OA treatment[13]. Furthermore, literature suggests several novel mechanisms that indicate genetic relationship between depression and OA[74], which brings potential for future studies to investigate this topic.

There's no doubt that biological factors play a role in osteoarthritis. On the other hand, literature show much evidence on psychological and social aspects of developing depression in OA. There are many features of psychological background in patients with OA. First of all, it is commonly known that OA has tremendous effect on quality of population existence and everyday activities as it accounts for 2,4% of all years lived with disability[20]. Its impact on poor psychological state may arise on behalf of exclusion from everyday activities. King L. K. et al conducted the study using multivariable logistic regression modeling and concluded that the number of hips and knees affected by symptomatic OA was the strongest determinant of walking difficulty. From 18,490 cohort participants 10% and 15,4% met the criteria of hip OA and knee OA diagnosis respectively[56]. They also stated that the predicted probability of difficulty in walking for a 60-year-old middle-income with OA in 2 hips/knees might occur in 40% of patients[56]. As a result of OA, disability, functional limitations and loss of independence occur[5]. Limitations generated by OA lead to gradual withdrawal from social life and mental health benefiting activities[75]. Sugai et al studied impact of knee dysfunction and pain on depression onset in a community-based 2-year cohort and the authors concluded that if normal activities, which involve going outside start to become a burden for an older adults with OA, they are more likely to develop depressive symptoms[76]. Impaired physical and social functioning may subsequently lead to a vicious cycle of negative coping strategies caused by both pain and affective symptoms[77-79]. Poor physical functioning itself was correlated with higher depression prevalence, across most of the depression definitions[80]. Occurrence of those problems result in impaired functioning in society and subsequently

social isolation, which is a psychosocial factor that may negatively influence concomitant depression in OA. Siviero et al in his prospective study proved a higher risk of social isolation of people with knee or hip osteoarthritis when compared to healthy individuals[81]. As above-mentioned studies prove it is possible that OA may directly or indirectly have impact on functioning in society and interactions with other people by increasing risk of a social isolation which subsequently induces depressive symptoms occurrence. Lack of social support, impaired physical functioning in society and everyday interactions are a factors of worsening of depression, literature reports that lack of a life partner is associated with higher depression prevalence[80].

Fear and stress that might be a result of OA course subsequently lead to sleep problems[7]. Lack of sleep is a proposed mechanism of contribution not only to depression[82], but also worsening of a OA course[83]. Furthermore, Parmelee et al proposed cross-sectional relationship between sleep disturbance, pain and depression. They highlighted sleep management as a medical care intervention that may prevent OA-related functional decline[84]. This might also be a mechanism in which these two diseases influence each other's course. Literature shows that psychological and social aspects of depression development in patients with OA are as important as biological and more longitudinal studies are required on this topic.

5. Depression impact on OA symptoms severity and treatment outcome

As possible interrelation between OA and depression has been shown by many studies, the problem of its impact on symptoms and treatment outcome has become a topic of discussion, over the past decade. Hawker et al suggested that pain influenced prevalence of depressed mood which exacerbated fatigue and disability and subsequently led to worsening of OA pain[13]. Furthermore, Rathbun A.M. et al estimated the dynamic causal effects of depressive symptoms on osteoarthritis knee pain and concluded that pain severity significantly increased with the persistence of depressed mood, yet the causal effect of depressive symptoms on OA knee pain did not change over time[79]. Zheng et al presented similar results as multisite pain significantly increased prevalence and development of depression, yet baseline depression was not correlated with knee joint symptomatic progression over 2 years[11]. Which supports the notion that managing of pain in OA patients may help to prevent and alleviate depressive symptoms[13, 60].

The topic of impact of depression on outcomes in OA treatment has been presented by many studies. Firstly, depression adversely impacts results of surgical interventions in few ways. Lopez-Olivo et al reported that patients with depression 6 months after total knee replacement had worse WOMAC scores and poorer total KSRS scores[85]. Furthermore, Hanusch et al in their research presented that patients experiencing depression had worse recovery rates from total knee replacement[86]. Concomitant depression in patients undergoing this procedure was also reported to have a relationship with worse postoperative pain[87]. In general, depression led to lower satisfaction rate of operation outcome[88]. Furthermore, an interaction between clinical depression symptoms and pain catastrophizing was associated with poor pain outcome expectation, which subsequently affected future total knee arthroplasty utilization[89]. Non-operative treatment of OA such as physical therapy was also reported to be influenced by comorbid depression[90]. Recent systematic review by Vajapey et al which included 30 studies showed that depression increases the risk of persistent pain, dissatisfaction, and complications after total joint arthroplasty (TJA)[91]. On the other hand, in systematic review by Bletterman et al they stated that healthcare providers who take care of patients awaiting for total joint arthroplasty should not overestimate the role of preoperative psychosocial factors as there's no proof of longitudinal relationship with psychosocial factors and outcomes of TJA. Reason behind this statement is due to risk of bias, poor quality of research and the failure to calculate trial sample sizes or the high rates of loss to follow-up in prospective longitudinal studies on this topic[92].

Overall, it seems that depression may have impact on treatment outcome and clinical management of patients with OA. Clinicians should include psychological and psychiatric approach to depression in OA to improve physical activity, OA treatment recovery and well-being of patients in general. However, we need more longitudinal studies on this issue with better quality research in the future.

6. Conclusion

In summary, this review presents several studies on prevalence of depression among patients with OA, its epidemiology, risk factors, possible mechanisms of development and finally depression impact on treatment outcome of osteoarthritis. There was some variability when it comes to incidence of depression between studies. Nevertheless, it seems to be certain that patients with OA are in a higher risk of concomitant depression when compared to a general population. Furthermore, most studies that touch on this subject suggest that depression in OA is associated with reduced quality of life and worse clinical outcomes of treatment.

Understanding of comorbid depression in OA patients has made significant progress, yet there are some issues that still need to be addressed in further research. Knowledge about the mechanisms of depression development, especially on neurobiological level remains limited. Changes in neurobiology, hormones and molecular biology have been partially presented in above-mentioned studies, yet we are far from understating biological background of depression development in OA patients. Future research that will manage to explain this phenomenon, might bring a whole new perspective on individualized and targeted depression treatment in OA.

Next problem that needs to be addressed is complexity of interrelating depression and OA as there are many psychosocial, clinical and demographic factors involved. Future studies should focus on separating potential coexisting causes of depression in OA patients to provide more relevant data in the future. Psychological aspects of osteoarthritis need further research too. Deeper understating of psychological and social factors such as social isolation, sleep deprivation and pain catastrophizing which lead to impaired functioning in society, might contribute to development of more complex OA treatment strategies which not only involve pharmacological and surgical options but also targeted psychotherapy. Further research based on high-quality randomized control trials should focus on developing definitive management strategies which ought to include screening, diagnosis and complex treatment of depression in OA patients.

Author's contribution:

Conceptualization: I.T.; Data curation, I.T., K.W., P.H., A.T., K.S.; Writing - rough preparation: I.T., K.D., A.Š., U.Ž.; Writing - review and editing: I.T., Z.K., D.M, H.C.K., K.A., J.P.; Supervision: I.T.; Project administration: I.T., K.D. All authors have read and agreed with the published version of the manuscript.

Financial support: No financial support was received.

Conflict of interest: The authors declare no conflict of interest.

1. Allen, K.D., L.M. Thoma, and Y.M. Golightly, *Epidemiology of osteoarthritis*. *Osteoarthritis Cartilage*, 2022. **30**(2): p. 184-195.
2. Woolf, A.D. and B. Pfleger, *Burden of major musculoskeletal conditions*. *Bull World Health Organ*, 2003. **81**(9): p. 646-56.
3. Nelson, A.E., *Osteoarthritis year in review 2017: clinical*. *Osteoarthritis Cartilage*, 2018. **26**(3): p. 319-325.

4. Hawker, G.A., *Osteoarthritis is a serious disease*. Clin Exp Rheumatol, 2019. **37 Suppl 120(5)**: p. 3-6.
5. Gignac, M.A., C. Cott, and E.M. Badley, *Adaptation to chronic illness and disability and its relationship to perceptions of independence and dependence*. J Gerontol B Psychol Sci Soc Sci, 2000. **55(6)**: p. P362-72.
6. Power, J.D., et al., *Fatigue in osteoarthritis: a qualitative study*. BMC Musculoskelet Disord, 2008. **9**: p. 63.
7. Hawker, G.A., et al., *The multidimensionality of sleep quality and its relationship to fatigue in older adults with painful osteoarthritis*. Osteoarthritis Cartilage, 2010. **18(11)**: p. 1365-71.
8. Stubbs, B., et al., *Prevalence of depressive symptoms and anxiety in osteoarthritis: a systematic review and meta-analysis*. Age Ageing, 2016. **45(2)**: p. 228-35.
9. Malhi, G.S. and J.J. Mann, *Depression*. Lancet, 2018. **392(10161)**: p. 2299-2312.
10. Wilkie, R., et al., *Reasons why multimorbidity increases the risk of participation restriction in older adults with lower extremity osteoarthritis: a prospective cohort study in primary care*. Arthritis Care Res (Hoboken), 2013. **65(6)**: p. 910-9.
11. Zheng, S., et al., *Depression in patients with knee osteoarthritis: risk factors and associations with joint symptoms*. BMC Musculoskelet Disord, 2021. **22(1)**: p. 40.
12. Gleicher, Y., et al., *A prospective study of mental health care for comorbid depressed mood in older adults with painful osteoarthritis*. BMC Psychiatry, 2011. **11**: p. 147.
13. Hawker, G.A., et al., *A longitudinal study to explain the pain-depression link in older adults with osteoarthritis*. Arthritis Care Res (Hoboken), 2011. **63(10)**: p. 1382-90.
14. Sale, J.E., M. Gignac, and G. Hawker, *The relationship between disease symptoms, life events, coping and treatment, and depression among older adults with osteoarthritis*. J Rheumatol, 2008. **35(2)**: p. 335-42.
15. Matcham, F., et al., *The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis*. Rheumatology (Oxford), 2013. **52(12)**: p. 2136-48.
16. Yohannes, A.M. and S. Caton, *Management of depression in older people with osteoarthritis: A systematic review*. Aging Ment Health, 2010. **14(6)**: p. 637-51.
17. Tang, X., et al., *The Prevalence of Symptomatic Knee Osteoarthritis in China: Results From the China Health and Retirement Longitudinal Study*. Arthritis Rheumatol, 2016. **68(3)**: p. 648-53.

18. Park, J.H., et al., *Prevalence of symptomatic hip, knee, and spine osteoarthritis nationwide health survey analysis of an elderly Korean population*. *Medicine (Baltimore)*, 2017. **96**(12): p. e6372.
19. Deshpande, B.R., et al., *Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity*. *Arthritis Care Res (Hoboken)*, 2016. **68**(12): p. 1743-1750.
20. *Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016*. *Lancet*, 2017. **390**(10100): p. 1211-1259.
21. *Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013*. *Lancet*, 2015. **386**(9995): p. 743-800.
22. Moussavi, S., et al., *Depression, chronic diseases, and decrements in health: results from the World Health Surveys*. *Lancet*, 2007. **370**(9590): p. 851-8.
23. Rodda, J., Z. Walker, and J. Carter, *Depression in older adults*. *Bmj*, 2011. **343**: p. d5219.
24. Shorey, S., E.D. Ng, and C.H.J. Wong, *Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis*. *Br J Clin Psychol*, 2022. **61**(2): p. 287-305.
25. Rosemann, T., et al., *Predictors of depression in a sample of 1,021 primary care patients with osteoarthritis*. *Arthritis Rheum*, 2007. **57**(3): p. 415-22.
26. Gad, B.V., et al., *Validity of patient-reported comorbidities before total knee and hip arthroplasty in patients older than 65 years*. *J Arthroplasty*, 2012. **27**(10): p. 1750-1756.e1.
27. Kirkness, C.S., et al., *Characterization of patients undergoing total knee arthroplasty in a real-world setting and pain-related medication prescriptions for management of postoperative pain*. *J Pain Palliat Care Pharmacother*, 2012. **26**(4): p. 326-33.
28. Scott, J.E., J.L. Mathias, and A.C. Kneebone, *Depression and anxiety after total joint replacement among older adults: a meta-analysis*. *Aging Ment Health*, 2016. **20**(12): p. 1243-1254.
29. El-Haddad, C., et al., *MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study*

- from current routine rheumatology care at four sites. RMD Open, 2017. 3(1): p. e000391.*
30. Chua, J.R., et al., *Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later. Arthritis Rheumatol, 2019. 71(8): p. 1276-1284.*
 31. Gandhi, R., et al., *Depression and the Overall Burden of Painful Joints: An Examination among Individuals Undergoing Hip and Knee Replacement for Osteoarthritis. Arthritis, 2015. 2015: p. 327161.*
 32. Luppino, F.S., et al., *Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry, 2010. 67(3): p. 220-9.*
 33. Plotnikoff, R., et al., *Osteoarthritis prevalence and modifiable factors: a population study. BMC Public Health, 2015. 15: p. 1195.*
 34. Dowlati, Y., et al., *A meta-analysis of cytokines in major depression. Biol Psychiatry, 2010. 67(5): p. 446-57.*
 35. Miller, R.E., R.J. Miller, and A.M. Malfait, *Osteoarthritis joint pain: the cytokine connection. Cytokine, 2014. 70(2): p. 185-93.*
 36. Loukov, D., et al., *Monocyte activation is elevated in women with knee-osteoarthritis and associated with inflammation, BMI and pain. Osteoarthritis Cartilage, 2018. 26(2): p. 255-263.*
 37. Attur, M., et al., *Increased interleukin-1 β gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum, 2011. 63(7): p. 1908-17.*
 38. Gómez, R., et al., *TLR4 signalling in osteoarthritis--finding targets for candidate DMOADs. Nat Rev Rheumatol, 2015. 11(3): p. 159-70.*
 39. Huang, Z.Y., et al., *Biomarkers of inflammation - LBP and TLR- predict progression of knee osteoarthritis in the DOXY clinical trial. Osteoarthritis Cartilage, 2018. 26(12): p. 1658-1665.*
 40. Jacobs, C.A., et al., *Rapid Progression of Knee Pain and Osteoarthritis Biomarkers Greatest for Patients with Combined Obesity and Depression: Data from the Osteoarthritis Initiative. Cartilage, 2020. 11(1): p. 38-46.*
 41. Li, M., et al., *The trajectories of depression symptoms and comorbidity in knee osteoarthritis subjects. Clin Rheumatol, 2022. 41(1): p. 235-243.*
 42. Parmelee, P.A., et al., *Pain, disability, and depression in osteoarthritis: effects of race and sex. J Aging Health, 2012. 24(1): p. 168-87.*

43. Ancelin, M.L., J. Scali, and K. Ritchie, *Hormonal therapy and depression: are we overlooking an important therapeutic alternative?* J Psychosom Res, 2007. **62**(4): p. 473-85.
44. Summer, B.E. and G. Fink, *Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat.* J Steroid Biochem Mol Biol, 1995. **54**(1-2): p. 15-20.
45. Soares, C.N. and B. Zitek, *Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability?* J Psychiatry Neurosci, 2008. **33**(4): p. 331-43.
46. Ryan, J., et al., *Estrogen receptor alpha gene variants and major depressive episodes.* J Affect Disord, 2012. **136**(3): p. 1222-6.
47. Oshima, Y., et al., *Localization of estrogen receptors alpha and beta in the articular surface of the rat femur.* Acta Histochem Cytochem, 2007. **40**(1): p. 27-34.
48. Riancho, J.A., et al., *Common variations in estrogen-related genes are associated with severe large-joint osteoarthritis: a multicenter genetic and functional study.* Osteoarthritis Cartilage, 2010. **18**(7): p. 927-33.
49. Ahrar, H., et al., *Association of rs2234693 and rs9340799 polymorphisms of estrogen Receptor-1 gene with radiographic defined knee osteoarthritis: A meta-analysis.* J Orthop, 2019. **16**(3): p. 234-240.
50. Judd, L.L. and H.S. Akiskal, *The clinical and public health relevance of current research on subthreshold depressive symptoms to elderly patients.* Am J Geriatr Psychiatry, 2002. **10**(3): p. 233-8.
51. Dines, P., W. Hu, and M. Sajatovic, *Depression in Later-life: An Overview of Assessment and Management.* Psychiatr Danub, 2014. **26 Suppl 1**: p. 78-84.
52. Gerrits, M.M., et al., *The impact of chronic somatic diseases on the course of depressive and anxiety disorders.* Psychother Psychosom, 2013. **82**(1): p. 64-6.
53. Previtali, D., et al., *Pain Trajectories in Knee Osteoarthritis-A Systematic Review and Best Evidence Synthesis on Pain Predictors.* J Clin Med, 2020. **9**(9).
54. Fonseca-Rodrigues, D., et al., *Correlation between pain severity and levels of anxiety and depression in osteoarthritis patients: a systematic review and meta-analysis.* Rheumatology (Oxford), 2021. **61**(1): p. 53-75.
55. Parmelee, P.A., et al., *Momentary Associations of Osteoarthritis Pain and Affect: Depression as Moderator.* J Gerontol B Psychol Sci Soc Sci, 2022. **77**(7): p. 1240-1249.

56. King, L.K., et al., *Impact of Osteoarthritis on Difficulty Walking: A Population-Based Study*. Arthritis Care Res (Hoboken), 2018. **70**(1): p. 71-79.
57. White, D.K., et al., *Association of Slow Gait Speed With Trajectories of Worsening Depressive Symptoms in Knee Osteoarthritis: An Observational Study*. Arthritis Care Res (Hoboken), 2017. **69**(2): p. 209-215.
58. Albert, S.M., J. Bear-Lehman, and S.J. Anderson, *Declines in mobility and changes in performance in the instrumental activities of daily living among mildly disabled community-dwelling older adults*. J Gerontol A Biol Sci Med Sci, 2015. **70**(1): p. 71-7.
59. Pearce, M., et al., *Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-analysis*. JAMA Psychiatry, 2022. **79**(6): p. 550-559.
60. Kroenke, K., et al., *Impact of pain on the outcomes of depression treatment: results from the RESPECT trial*. Pain, 2008. **134**(1-2): p. 209-15.
61. Simon, G.E., *Treating depression in patients with chronic disease: recognition and treatment are crucial; depression worsens the course of a chronic illness*. West J Med, 2001. **175**(5): p. 292-3.
62. Bhattacharya, R., C. Shen, and U. Sambamoorthi, *Excess risk of chronic physical conditions associated with depression and anxiety*. BMC Psychiatry, 2014. **14**: p. 10.
63. Kapoor, M., et al., *Role of proinflammatory cytokines in the pathophysiology of osteoarthritis*. Nat Rev Rheumatol, 2011. **7**(1): p. 33-42.
64. Berenbaum, F., *Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)*. Osteoarthritis Cartilage, 2013. **21**(1): p. 16-21.
65. Chow, Y.Y. and K.Y. Chin, *The Role of Inflammation in the Pathogenesis of Osteoarthritis*. Mediators Inflamm, 2020. **2020**: p. 8293921.
66. D'Mello, C. and M.G. Swain, *Immune-to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression*. Curr Top Behav Neurosci, 2017. **31**: p. 73-94.
67. Fiksdal, A., et al., *Associations between symptoms of depression and anxiety and cortisol responses to and recovery from acute stress*. Psychoneuroendocrinology, 2019. **102**: p. 44-52.
68. Zajkowska, Z., et al., *Cortisol and development of depression in adolescence and young adulthood - a systematic review and meta-analysis*. Psychoneuroendocrinology, 2022. **136**: p. 105625.

69. Vreeburg, S.A., et al., *Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study*. Arch Gen Psychiatry, 2009. **66**(6): p. 617-26.
70. Wingenfeld, K., et al., *HPA axis reactivity in chronic pelvic pain: association with depression*. J Psychosom Obstet Gynaecol, 2009. **30**(4): p. 282-6.
71. Mutso, A.A., et al., *Abnormalities in hippocampal functioning with persistent pain*. J Neurosci, 2012. **32**(17): p. 5747-56.
72. Borsook, D., S. Sava, and L. Becerra, *The pain imaging revolution: advancing pain into the 21st century*. Neuroscientist, 2010. **16**(2): p. 171-85.
73. Li, X., et al., *Osteoarthritis Was Associated With a Faster Decline in Hippocampal Volumes in Cognitively Normal Older People*. Front Aging Neurosci, 2020. **12**: p. 190.
74. Zhang, F., S. Rao, and A. Baranova, *Shared genetic liability between major depressive disorder and osteoarthritis*. Bone Joint Res, 2022. **11**(1): p. 12-22.
75. Prince, M.J., et al., *A prospective population-based cohort study of the effects of disablement and social milieu on the onset and maintenance of late-life depression. The Gospel Oak Project VII*. Psychol Med, 1998. **28**(2): p. 337-50.
76. Sugai, K., et al., *Association Between Knee Pain, Impaired Function, and Development of Depressive Symptoms*. J Am Geriatr Soc, 2018. **66**(3): p. 570-576.
77. Campbell, L.C., D.J. Clauw, and F.J. Keefe, *Persistent pain and depression: a biopsychosocial perspective*. Biol Psychiatry, 2003. **54**(3): p. 399-409.
78. Elliott, A.M., et al., *The course of chronic pain in the community: results of a 4-year follow-up study*. Pain, 2002. **99**(1-2): p. 299-307.
79. Rathbun, A.M., et al., *Dynamic Effects of Depressive Symptoms on Osteoarthritis Knee Pain*. Arthritis Care Res (Hoboken), 2018. **70**(1): p. 80-88.
80. Sjöberg, L., et al., *Prevalence of depression: Comparisons of different depression definitions in population-based samples of older adults*. J Affect Disord, 2017. **221**: p. 123-131.
81. Siviero, P., et al., *Association Between Osteoarthritis and Social Isolation: Data From the EPOSA Study*. J Am Geriatr Soc, 2020. **68**(1): p. 87-95.
82. Li, L., et al., *Insomnia and the risk of depression: a meta-analysis of prospective cohort studies*. BMC Psychiatry, 2016. **16**(1): p. 375.
83. Ni, J., et al., *Evidence for causal effects of sleep disturbances on risk for osteoarthritis: a univariable and multivariable Mendelian randomization study*. Osteoarthritis Cartilage, 2022. **30**(3): p. 443-450.

84. Parmelee, P.A., C.A. Tighe, and N.D. Dautovich, *Sleep disturbance in osteoarthritis: linkages with pain, disability, and depressive symptoms*. Arthritis Care Res (Hoboken), 2015. **67**(3): p. 358-65.
85. Lopez-Olivo, M.A., et al., *Psychosocial determinants of outcomes in knee replacement*. Ann Rheum Dis, 2011. **70**(10): p. 1775-81.
86. Hanusch, B.C., et al., *Effects of psychological distress and perceptions of illness on recovery from total knee replacement*. Bone Joint J, 2014. **96-b**(2): p. 210-6.
87. Pan, X., et al., *Depression and Anxiety Are Risk Factors for Postoperative Pain-Related Symptoms and Complications in Patients Undergoing Primary Total Knee Arthroplasty in the United States*. J Arthroplasty, 2019. **34**(10): p. 2337-2346.
88. Bierke, S., et al., *Midterm Effect of Mental Factors on Pain, Function, and Patient Satisfaction 5 Years After Uncomplicated Total Knee Arthroplasty*. J Arthroplasty, 2020. **35**(1): p. 105-111.
89. Riddle, D.L., et al., *Poor expectations of knee replacement benefit are associated with modifiable psychological factors and influence the decision to have surgery: A cross-sectional and longitudinal study of a community-based sample*. Knee, 2017. **24**(2): p. 354-361.
90. Uckun, A.C., et al., *The Role of Pain Catastrophizing and Depression in the Outcomes of Physical Therapy in a Prospective Osteoarthritis Cohort*. Pain Physician, 2020. **23**(2): p. 209-218.
91. Vajapey, S.P., et al., *Outcomes of total joint arthroplasty in patients with depression: A systematic review*. J Clin Orthop Trauma, 2021. **18**: p. 187-198.
92. Bletterman, A.N., et al., *Preoperative psychosocial factors predicting patient's functional recovery after total knee or total hip arthroplasty: a systematic review*. Clin Rehabil, 2018. **32**(4): p. 512-525.